Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis

Therapeutic Drug Monitoring

Volumn 28, Issue 2, 2006, Pages 219-225

  Wilms, E B ^a   Touw, D J ^a   Heijerman, H G M ^b  

^a Central Hospital Pharmacy   (Netherlands)

^b LEYENBURG HOSPITAL   (Netherlands)

Author keywords

Azithromycin; Cystic fibrosis; Pharmacokinetics; Polymorphonuclear neutrophils; Sputum concentration; Therapeutic drug monitoring

Indexed keywords

AZITHROMYCIN;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CYSTIC FIBROSIS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; FEMALE; HUMAN; LONG TERM CARE; MALE; NEUTROPHIL; PRIORITY JOURNAL; SPUTUM ANALYSIS;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; MALE; NEUTROPHILS; PSEUDOMONAS INFECTIONS; REPRODUCIBILITY OF RESULTS; SPUTUM; TREATMENT OUTCOME;

EID: 33748165610     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000195617.69721.a5     Document Type: Article

References (25)

1. Mazzei T, Mini E, Novelli A, et al. Chemistry and mode of action of macrolides. J Antimicrob Chemother. 1993;31(Suppl C):1-9.
2. Amsden GW, Gray CL. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother. 2001;47:61-66.
3. Wildfeuer A, Laufen H, Zimmermann T. Distribution of orally administered azithromycin in various blood compartments. Int J Clin Pharmacol Ther. 1994;32:356-360.
4. Equi A, Balfour-Lynn IM, Bush A, et al. Long-term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360:978-984.
5. Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 1998;351:420.
6. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749-1756.
7. Wolter J, Seeney S, Bell S, et al. Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57:212-216.
8. Ichimiya T, Takeoka K, Hiramatsu K, et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy. 1996;42:186-191.
9. Takeoka K, Ichimiya T, Yamasaki T, et al. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy. 1998;44:190-197.
10. Tateda K, Comte R, Pechere JC, et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2001;45:1930-1933.
11. Conte JE Jr, Golden J, Duncan S, et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother. 1996;40:1617-1622.
12. Morris DL, De Souza A, Jones JA, et al. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur J Clin Microbiol Infect Dis. 1991;10:859-861.
13. Olsen KM, San Pedro G, Gann LP, et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother. 1996;40:2582-2585.
14. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother. 1996;40:2375-2379.
15. Re C. Use of modulators of airway inflammation in patients with CF. Clin Rev Allergy Immunol. 2002;23:29-39.
16. Wilms E, Trumpie H, Veenendaal W, et al. Quantitative determination of azithromycin in plasma, blood and isolated neutrophils by liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection. J Chromatogr B. 2005;814:37-42.
17. Nibbering P, Zomerdijk T, Corsel-van Tilburg A, et al. Mean cell volume of human blood leucocytes and resident and activated murine macrophages. J Immunol Meth. 1990;129:143-145.
18. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22:155-163.
19. Mandell GL, Coleman E. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother. 2001;45:1794-1798.
20. Hand WL, Hand DL. Characteristics and mechanism of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents. 2001;18:419-425.
21. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. J Antimicrob Chemother. 1990;34:1056-1060.
22. Galichet, ed. Clarke's Analysis of Drugs and Poisons. 3rd ed. London: Pharmaceutical Press; 2004.
23. De Duve C, De Barsy T, Poole B, et al. Lysosomotropic agents. Biochem Pharmacol. 1974;23:2495-2531.
24. Hollemans M, Oude Elferink R, De Groot PG, et al. Accumulation of weak bases in relation to intralysosomal pH in cultured human skin fibroblasts. Biochim Biophys Acta. 1981;643:140-151.
25. Hubeau C, Lorenzato M, Couetil J, et al. Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa. Clin Exp Immunol. 2001;124:69-76.